Literature DB >> 16541097

Negative association between the chemokine receptor CCR5-Delta32 polymorphism and rheumatoid arthritis: a meta-analysis.

S Prahalad1.   

Abstract

Rheumatoid arthritis (RA) is characterized by synovial inflammation mediated by T-cells, monocytes and macrophages. The homing of these cells to the inflamed synovium is regulated by chemokine-receptors and their ligands. A 32-basepair deletion (Delta32) in the gene encoding CCR5, a chemokine-receptor, results in a non-functional receptor. A negative association between CCR5-Delta32 and RA has been described, although other studies found no associations. Furthermore, the observation that individuals homozygous for CCR5-Delta32 develop RA has raised questions about the role of CCR5-Delta32. This meta-analysis of all published case-control association studies confirms the negative association between CCR5-Delta32 and RA (Odds Ratio=0.65; 95% confidence intervals=0.55-0.77; P<0.0001), suggesting that CCR5-Delta32 is protective against the development of RA. CCR5 blockade in animal models of RA results in amelioration of arthritis, suggesting that CCR5 blockade could also modify disease in patients with RA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16541097      PMCID: PMC3104293          DOI: 10.1038/sj.gene.6364298

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  28 in total

Review 1.  The search for rheumatoid arthritis susceptibility genes: a call for global collaboration.

Authors:  Damini Jawaheer; Peter K Gregersen
Journal:  Arthritis Rheum       Date:  2002-03

2.  Genetic variation in CCR5 does not predict clinical outcome in inflammatory arthritis.

Authors:  Sally John; Simon Smith; Jonathan F Morrison; Deborah Symmons; Jane Worthington; Alan Silman; Anne Barton
Journal:  Arthritis Rheum       Date:  2003-12

3.  Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease.

Authors:  Kirk E Lohmueller; Celeste L Pearce; Malcolm Pike; Eric S Lander; Joel N Hirschhorn
Journal:  Nat Genet       Date:  2003-01-13       Impact factor: 38.330

4.  A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses.

Authors:  Yi-Fu Yang; Takao Mukai; Ping Gao; Nobuya Yamaguchi; Shiro Ono; Hiroshi Iwaki; Satoshi Obika; Takeshi Imanishi; Takahiro Tsujimura; Toshiyuki Hamaoka; Hiromi Fujiwara
Journal:  Eur J Immunol       Date:  2002-08       Impact factor: 5.532

5.  A strong signature of balancing selection in the 5' cis-regulatory region of CCR5.

Authors:  Michael J Bamshad; Srinivas Mummidi; Enrique Gonzalez; Seema S Ahuja; Diane M Dunn; W Scott Watkins; Stephen Wooding; Anne C Stone; Lynn B Jorde; Robert B Weiss; Sunil K Ahuja
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

6.  Publication bias in clinical research.

Authors:  P J Easterbrook; J A Berlin; R Gopalan; D R Matthews
Journal:  Lancet       Date:  1991-04-13       Impact factor: 79.321

7.  Selective lymphocyte chemokine receptor expression in the rheumatoid joint.

Authors:  J H Ruth; J B Rottman; K J Katschke; S Qin; L Wu; G LaRosa; P Ponath; R M Pope; A E Koch
Journal:  Arthritis Rheum       Date:  2001-12

8.  Biological relevance of the polymorphism in the CCR5 gene in refractory and non-refractory rheumatoid arthritis in Mexicans.

Authors:  J A Zúñiga; C Villarreal-Garza; E Flores; R Barquera; N Pérez-Hernández; J V Montes de Oca; M H Cardiel; G Vargas-Alarcón; J Granados
Journal:  Clin Exp Rheumatol       Date:  2003 May-Jun       Impact factor: 4.473

Review 9.  Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations.

Authors:  Julian Little; Linda Bradley; Molly S Bray; Mindy Clyne; Janice Dorman; Darrell L Ellsworth; James Hanson; Muin Khoury; Joseph Lau; Thomas R O'Brien; Nat Rothman; Donna Stroup; Emanuela Taioli; Duncan Thomas; Harri Vainio; Sholom Wacholder; Clarice Weinberg
Journal:  Am J Epidemiol       Date:  2002-08-15       Impact factor: 4.897

10.  Macrophage inflammatory protein-1 alpha. A novel chemotactic cytokine for macrophages in rheumatoid arthritis.

Authors:  A E Koch; S L Kunkel; L A Harlow; D D Mazarakis; G K Haines; M D Burdick; R M Pope; R M Strieter
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

View more
  33 in total

1.  The strength of the chemotactic response to a CCR5 binding chemokine is determined by the level of cell surface CCR5 density.

Authors:  Caroline Desmetz; Yea-Lih Lin; Clément Mettling; Pierre Portalès; Herisoa Rabesandratana; Jacques Clot; Pierre Corbeau
Journal:  Immunology       Date:  2006-12       Impact factor: 7.397

2.  Peripheral blood T4 cell surface CCR5 density as a marker of activity in rheumatoid arthritis treated with anti-CD20 monoclonal antibody.

Authors:  Pierre Portalès; Sylvie Fabre; Thierry Vincent; Caroline Desmetz; Brigitte Réant; Danièle Noël; Jacques Clot; Christian Jorgensen; Pierre Corbeau
Journal:  Immunology       Date:  2009-03-26       Impact factor: 7.397

Review 3.  Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework.

Authors:  David Cook; Dearg Brown; Robert Alexander; Ruth March; Paul Morgan; Gemma Satterthwaite; Menelas N Pangalos
Journal:  Nat Rev Drug Discov       Date:  2014-05-16       Impact factor: 84.694

4.  Association of two functional polymorphisms in the CCR5 gene with juvenile rheumatoid arthritis.

Authors:  S Prahalad; J F Bohnsack; L B Jorde; A Whiting; B Clifford; D Dunn; R Weiss; M Moroldo; S D Thompson; D N Glass; M J Bamshad
Journal:  Genes Immun       Date:  2006-06-15       Impact factor: 2.676

5.  CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission.

Authors:  Jean K Lim; David H McDermott; Andrea Lisco; Gregory A Foster; David Krysztof; Dean Follmann; Susan L Stramer; Philip M Murphy
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

6.  Association of the CCR5 gene with juvenile idiopathic arthritis.

Authors:  A Hinks; P Martin; E Flynn; S Eyre; J Packham; A Barton; J Worthington; W Thomson
Journal:  Genes Immun       Date:  2010-05-13       Impact factor: 2.676

7.  CCR5 expression levels influence NFAT translocation, IL-2 production, and subsequent signaling events during T lymphocyte activation.

Authors:  Jose F Camargo; Marlon P Quinones; Srinivas Mummidi; Sowmya Srinivas; Alvaro A Gaitan; Kazi Begum; Fabio Jimenez; Scott VanCompernolle; Derya Unutmaz; Seema S Ahuja; Sunil K Ahuja
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

Review 8.  Immunogenetics of juvenile idiopathic arthritis: A comprehensive review.

Authors:  Aimee O Hersh; Sampath Prahalad
Journal:  J Autoimmun       Date:  2015-08-21       Impact factor: 7.094

9.  Chemokine receptor 5 Δ32 polymorphism and systemic lupus erythematosus, vasculitis, and primary Sjogren's syndrome. Meta-analysis of possible associations.

Authors:  Y H Lee; J-H Kim; G G Song
Journal:  Z Rheumatol       Date:  2014-11       Impact factor: 1.372

10.  Negative association of the chemokine receptor CCR5 d32 polymorphism with systemic inflammatory response, extra-articular symptoms and joint erosion in rheumatoid arthritis.

Authors:  Manuela Rossol; Matthias Pierer; Sybille Arnold; Gernot Keysser; Harald Burkhardt; Christoph Baerwald; Ulf Wagner
Journal:  Arthritis Res Ther       Date:  2009-06-18       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.